TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
· Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Johnson & Johnson News
- Region
- USA
- Scope
- Industry
- Published
- July 23, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
· Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and...
Source route
Continue on jnj.com
Leave the platform to read the original full article on the publisher site.
Source: Johnson & Johnson News
Scope: Industry
Related coverage